📢 Have you finished your PhD (or are about to) and you are looking for an exciting postdoc opportunity? Check out fully funded 3yr postdoc position in Cologne CECAD Cologne 🇩🇪🇪🇺on #CLL&cancer evolution&plasticity! Apply here: shorturl.at/mHR06 DM/📧 to get in touch!

📢 New job opening in the lab! We are looking for a PhD student with a computational background and interest in AI-driven data analysis 🔬💻🧠: nature.com/naturecareers/… DM/📨 to get in touch!

CONGRESS #ASCO24 | Peter Borchmann, MD #cioabcd presented the first report of the final analysis of phase III #HD21 trial of PET2-individualized BrECADD regimen vs intensified BEACOPP in patients with advanced-stage #HodgkinLymphoma. BrECADD had superior efficacy (PFS 94.3% vs

📢Our latest review is online! We discuss how macrophages influence CLL progression and frontline therapy response, a topic initiated and contemplated by our youngest lab member @hjestrabek. Such a great joy for me to work with the new Gen of 2000s 🎉 sciencedirect.com/science/articl…

Time to make your vote count in the European Election 2024 #EUelections24 #Europawahl2024

Unmet needs in CLL in the era of targeted therapies. #MichaelHallek at #EHA2024 Double exposed does not equal Double refractory in the R/R CLL setting

New ESMO - Eur. Oncology - European Hematology Association Guidelines on Chronic Lymphocytic Leukemia #CLL presented at #EHA2024. Frailty assessment is still needed to make a treatment decision in the era of novel agents #geriheme #lymsm #leusm

The phrase ‘metastasis accounts for 90% of cancer deaths’ is one of the most widely used in cancer research, yet it is overly simplistic, imprecise, and it is difficult to find any primary analysis supporting the statement. | → rdcu.be/dLgsZ ← | 🧵(1/5)

New article in press: ESMO Clinical Practice Guideline interim update on new targeted therapies in the first-line and at relapse of chronic lymphocytic leukaemia doi.org/10.1016/j.anno…

It’s my pleasure to share a preprint describing @falchi_lorenzo and Vardhana Lab explorations into how bispecific antibodies work in B-cell non-Hodgkin lymphomas: medrxiv.org/cgi/content/sh…

Bei #Vergiftungen schnell richtig handeln: Die Website ToxDocs versorgt Rettungsdienst & Notaufnahme mit den wichtigsten Infos. Für diese Innovation der Notfallmedizin gab‘s den Hans-Werner-Feder Preis 2024 für Dr. Christoph Hüser von der #Uniklinik #Köln. uk-koeln.de/uniklinik-koel…

Excited to share our Richard Lewis Michael Hallek perspective on double-refractory (2R) #CLL, now in Blood Journal. 2R pts are a growing challenge with poor outcomes. We outline the current landscape and explore targets in the tumor microenvironment. #CLL doi.org/10.1182/blood.…

Check out our latest paper in Journal of Clinical Oncology on surrogacy of endpoints in 1L #CLL trials! Led by Florian Simon, we systematically studied the association of PFS and MRD with OS. Some findings in a brief 🧵 👇 ascopubs.org/doi/10.1200/JC…

Online Now: Universal and tissue-specific fibroblasts in chronic inflammation and cancer dlvr.it/TDk9Jz

Spatial oncology: Translating contextual biology to the clinic dlvr.it/TFSSWb

🧬 Neue Einblicke beim #HodgkinLymphom: Forschende der #Uniklinik #Köln haben mittels Sequenzierung zirkulierender Tumor-DNA eine biologische Klassifikation entwickelt. Diese verbessert die Prognoseabschätzung bei der Erkrankung: uk-koeln.de/uniklinik-koel… #Onkologie #Forschung

Beyond excited that the first paper of my PhD journey is out in SNO today, reviewing the brain metastatic immune microenvironment. Super grateful for the great collaborative effort, particularly the guidance of Hien Nguyen and Roland Goldbrunner ! academic.oup.com/neuro-oncology…

#ASH24 #ALL #Phpos Dasatinib+Blina induces more profound immune modulation compared to Ponatinib+Blina. Post-hoc analysis from D-ALBA, GIMEMA investigators Overall relapses were low in both groups. #leusm

Very nice illustration of currently approved therapies for CLL. Note the progress that has been made, with targeted agents replacing chemotherapy! However, double refractory patients relapsing to BTKi and BCL2i will be an upcoming challenge in #CLL future!